Das Bild zeigt rechts ein Trichterglas mit blauer Flüssigkeit und Glasstab zum Umrühren. Daneben steht ein Reagenzglasständer mit Reagenzgläsern, die ebenfalls blaue Flüssigkeit enthalten. Im Hintergrund ist ein Forscher zu sehen, der in der rechten Hand eine Pipette hält.

RADOX

You are here:

RADOX- RADical reduction of OXidative stress in cardiovasular diseases

EU (FP7-PEOPLE-2012-ITN; GA 316738),

Coordinator Charité-Universitätsmedizin Berlin

PI: Vera Regitz-Zagrosek, 2013-2016 Partner: Keith Channon (University of Oxford, United Kingdom), Thomas Krieg (University of Cambridge, United Kingdom), Rhian Touyz (University of Glasgow, United Kingdom), Stefan Janssens (University of Leuven, Belgium), Fabio di Lisa (University of Padua, Italy), Guillermo Zalba (University of Navarra, Pamplona, Spain), Barbara Albrech-Küppers/Tobias Marquardt (Bayer Wuppertal, Germany), Uli Schotten (University of Maastricht, Netherlands)

Cardiovascular diseases (CVD) constitute a major and increasing health and ensuing economic burden in developed countries. The prediction is that the prevalence of these conditions will increase by ~60% over the next 20 years. Subsequently the development of novel treatments for patients with CVD becomes more and more urgent. Oxidative stress is a major molecular contributor to the pathogenesis of CVD; however, oxidative stress related therapeutic strategies are still missing. The RADOX consortium linked excellent investigators highly active in the field of oxidative stress-signaling, and strongly enhanced collaborative research and integrated complementary interests to obtain innovative science and outstanding in-depth integrative multidisciplinary training possibilities. This RADOX consortium consisted of 9 full partners (8 academic and 1 private) and 4 associate private partners and trained at the end 15 PhD-students, and 4 junior post doctoral fellows. The mission of this ITN-project was to create future leaders in the field of redox and oxidative stress-biology and to lay the foundation for a robust translational research and training program in this field. Specifically, we aimed to characterize the specific sources of reactive oxygen species (ROS) and their interaction in cardiovascular disease and to use this knowledge to develop diagnostic tools for the detection and quantification of ROS and their subcellular targets. We wanted to build a basis for the development of new therapeutic strategies which modulate the activity of these specific sources of ROS. Therefore, the project objectives also complied perfectly with the FP7 focus on identification and validation of novel, therapeutically relevant targets for the development of new medications for cardiovascular pathologies.

ITN RADOX

[Englische Übersetzung]

The project was launched on January 1st 2013 and is funded by European Commission.

Cardiovascular disease (CVD) constitutes a major and increasing health burden in developed countries. The prediction is that the prevalence of these conditions will increase by ~60% over the next 20 years. Therefore, the development of novel treatments for patients with CVD becomes more and more urgent. Oxidative stress is an important molecular contributor to the pathogenesis of CVD. However, oxidative stress-related therapeutic strategies are still missing. This ITN consortium links investigators highly active in the field of oxidative stress-signalling, and will strongly enhance collaborative research and integrate complementary interests to obtain innovative science and outstanding in-depth integrative multidisciplinary training possibilities. The scientific aims of this ITN proposal entitled 'RADical reduction of OXidative stress in cardiovascular disease (RADOX)' are to characterize the specific sources of reactive oxygen species (ROS) and their interaction in CVD and to use this knowledge to develop diagnostic tools for the detection and quantification of ROS and their subcellular targets. This will lead to new therapeutic strategies which modulate the activity of these specific sources of ROS. This RADOX consortium, containing 9 full partners (8 academic and 1 private) and 7 associate partners (7 private) will train 11 ESR and 4 ER. The mission of this ITN consortium is to create in a period of 4-years the future leaders in this field. Our trainees will receive unequalled multidisciplinary scientific and transferable skills training which will make them ready for leading positions in academia or industry. The training in this program will be at 3 levels i.e. through research under supervision, transferable skills and secondments and will have a strong intersectoral, international and interdisciplinary character. Afterwards, the RADOX structure will serve as a European platform for outstanding doctoral training and oxidative stress research. 

Grant Agreement No. 316738

http://radox.org